2015, Number 4
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2015; 53 (4)
CD200 protein, bad prognostic in patients with multiple myeloma
Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, Pérez-Retiguin F, Reyes-Maldonado E, Maillet D, Montiel-Cervantes LA
Language: Spanish
References: 17
Page: 438-443
PDF size: 245.27 Kb.
ABSTRACT
Background: Multiple myeloma (MM) is a monoclonal gammopathy
characterized by abnormal proliferation of malignant plasma cells. The
median overall survival rate has changed from 2-3 to 5-6 or more years
with the introduction of novel agents. Recently CD200 protein has been
described as an immunosuppressive protein that confers a poor prognostic
factor in several neoplastic diseases, including MM. The purpose
of our study was to determine CD200 protein in plasma cells of newly
diagnosed patients with MM and in CD3+ lymphocytes of healthy donors.
Methods: 35 newly diagnosed MM patients and 25 healthy donors were
studied. For fl ow cytometry tests, a FacsCalibur device and CellQuest-
Pro software were used. Monoclonal antibodies for CD38 (PeCyC5),
CD138 (APC), and CD200 (PE) were used. The statistical analysis was
performed with SPSS 19v. Mann-Whitney U test, Kaplan-Meier survival
curves with Log-Rank tests were done when indicated.
Results: The frequencies of anemia, hypercalcemia, increased in LDH,
serum creatinine and b2-microglobulin were 68%, 34%, 20%, 22% and
45% respectively. The treatment consisted in MPT 20 (57%), Thal-Dex
8 (23%), and VAD 7 (20%). Five patients (14%) achieved complete
response, 17 (49%) partial response, and 13 (37%) minor response or
failure to treatment.
Conclusions: CD200 is a poor prognostic factor for overall survival in
multiple myeloma patients. Bone marrow CD3 lymphocytes from MM
patients express CD200 protein in higher proportion than healthy donors.
REFERENCES
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78(1):21-33.
Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratifi cation of Myeloma and Risk- Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013;88(4):360-76.
Wright,G.J. et al. Characterization of the CD200 receptor family in mice and humans and the ir interactions with CD200. J. Immunol 2003;171:3034-3046.
Jenmalm,M.C. et al. Regulation of myeloid cell function through the CD200 receptor. J. Immunol. 2006; 176:191-199.
Cherwinski, H.M. et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J. Immunol.2005;174:1348-1356.
Gorczynski, R.M. et al. Induction of toleranceinducing antigen- presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 2004;77:1138-1144.
Moreaux, J. et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-4197.
Tonks, A. et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007;21:566-568.
Olteanu H, Harrington AM, Hari P, Kroft SH. CD200 expression in plasma cell myeloma. Br J Haematol 2011;153 (3) :408-411.
Conticello C, Giuffrida R, Parrinello N. et al. CD200 expression in patients with Multiple Myeloma: Another piece of the puzzle. Leuk Res 2013;37:1616-1621.
Liao KL, Bai XF, Friedman A. The role of CD200- CD200R in tumor immuneevasion. J Theoret Biol 2013;328:65-76.
Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophysl Res Commun 2007; 364:778-782.
Najar M, Raicevic G, Jebbawi F, Bruyn CD, Meuleman N, Bron D, Toungouz M, Lagneaux L. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett 2012;146:50-56.
Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B. CD200: a putaive therapeutic target in cancer. Biochem Biophys Res Commun 2008;366:117-22.
Olteanu H, Harrington AM, Hari P, Kroft SH. CD200 expression in plasma cellmyeloma. Br J Haematol 2011;153(3):408-11.
Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms. Am J Clin Pathol 2010;134(5 (November)):726-33.
Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol 2012;137:93–100.
Full text